Anti-CD19 chimeric antigen receptor T-cell therapy in B-cell lymphomas: current status and future directions.
Julio C ChavezFarah YassineJose Sandoval-SusMohamed A Kharfan-DabajaPublished in: International journal of hematologic oncology (2021)
Anti-CD19 CAR T-cell therapy is a viable option for poor risk refractory B-cell NHLs.